ArticleBMC infectious diseases2026
HIV-related neurological complications in Cameroon in the era of Test and Treat strategy: prevalence and mortality.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurological complications are common in HIV infection and can occur at any stage of the disease. These conditions could be associated with poor outcome. This study aimed to determine the prevalence of HIV-related neurological complications and to identify factors associated with mortality among these patients. MATERIALS AND
methodThis was a retrospective cohort study from January 1st, 2016, to 31 December 31st, 2023, in Laquintinie and General hospitals in Douala. We reviewed all records of patients living with HIV, and we included those with HIV-related neurological complications. Demographic, clinical, laboratory, neuroimaging, and therapeutic data were collected. Univariate and multivariate logistic regression analysis were performed to identify predictive factors of mortality.
resultsAmong the 15,521 admissions, 1,058 (6.8%) were people living with HIV (PLVIH), including 435 (41.1%) admitted for HIV-related neurological complications. The mean age was 45.5 ± 11.7 years, and 58.4% were women. CD4 count and viral load were unavailable in more than 85% of cases. Cerebral toxoplasmosis (33.3%), meningoencephalitis of undetermined etiology (25.3%), and cryptococcal meningitis (9.2%) were the most common etiologies. The in-hospital mortality rate among patients with HIV-related neurological complications was 29.4%. In the multivariable analysis, cerebral toxoplasmosis (aOR:4.0, 95% CI:1.4–11.0, p = 0.009) and meningoencephalitis of undetermined etiology (aOR: 1.8, 95% CI: 1.0–3.1, p = 0.038) were independent predictors of in-hospital mortality.
conclusionHIV-related neurological complications remain common and deadly in our setting, with cerebral toxoplasmosis and meningoencephalitis of unknown etiology emerge as major contributors to mortality. Limited access to immunovirological and advanced diagnostic testing likely contribute to delayed diagnosis and poor outcomes. Prospective studies are needed to refine diagnostic algorithm and improve survival in affected patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.